Seres - Model SER-155 - Investigational, Oral, Rationally Designed, Fermented Microbiome Therapeutic
SER-155 is an investigational, oral, rationally designed, fermented microbiome therapeutic designed to reduce the incidence of gastrointestinal infections, bacteremia, and graft versus host disease (GvHD) in immunocompromised patients, including patients receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT).
SER-155 is a multifunctional consortium of commensal bacteria designed based on human clinical insights. SER-155 is designed to augment the following microbiome functions, which are associated with better survival and lower rates of infection and GvHD in patients undergoing stem cell transplantation →
Antibiotic-resistant infections, GvHD and mortality are frequent serious complications of organ or stem cell transplantation. Antibiotics used to treat infections in this patient population are not always effective and can have significant side effects. Current therapies for the prevention of GvHD rely on broad immunosuppression, which increases the risk of infection, and has limited efficacy for a significant proportion of patients.
Status of clinical developmentInitiation of clinical development in process.